No serious adverse events occurred

No device-related serious adverse events were experienced at the elevated levels, and independent dosimetry experts have concluded from the data that 400 Gy is the optimum dose

All 48 patients treated in the studies were given four vaccinations, which were well tolerated, with no serious adverse effects associated with the vaccine candidates observed...The DMC reviewed all unblinded adverse events in the safety study including all serious adverse events and all adverse cardiovascular and breast cancer events in 1,055 women with 883 women-years of exposure

No drug-related serious adverse events were reported

In February, the company suspended enrollment in a Phase II trial after two patients experienced serious adverse events that were probably related to treatment with AT2220

There were no Zerenex-related serious adverse events reported

There were no serious adverse events in the clinical trial

Findings of the study showed no drug-related serious adverse events, and the therapy induced detectable exon skipping at a very low drug dose of 0.9 mg

The drug was well tolerated in all 15 patients, and there were no drug-related serious adverse events reported at any of the five dose levels (0.2 mg/eye to 1.8 mg/eye

ANA773 was well tolerated, with no serious adverse events

Oramed Pharmaceuticals Inc., of Jerusalem, reported positive results from a Phase IIa study of ORMD-0801, its oral insulin capsule, in Type I diabetics, showing that the product was well tolerated by patients, with no serious adverse events observed

Overall, the study achieved its primary objective of demonstrating safety and tolerability of ALN-RSV01, and there were no drug-related serious adverse events or discontinuations, and there were no clinically significant differences in the overall adverse event profile between ALN-RSV01 and placebo

Funxional Therapeutics Ltd., of Cambridge, UK, said its first Phase I study of FX125L showed the anti-inflammatory drug to be well tolerated with no serious adverse events or withdrawals

There have been no drug-related serious adverse events to date

The study follows a recently completed Phase I trial in which safety and tolerability were successfully demonstrated in 120 healthy volunteers with no reported serious adverse events

No drug-related serious adverse events were reported in either study, and no patients developed anti-ENB-0040 antibodies

Analysis also demonstrated that DX-88 was efficacious in treating all acute attack locations (laryngeal, abdominal, peripheral) and was well tolerated, with no treatment-related serious adverse events

That means patients already enrolled who are not experiencing serious adverse events may continue to receive treatment, though no additional patients may be enrolled

In addition, no serious adverse events have been recorded, and there have been no instances of skin irritation to date